Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

New research links childhood adversity with later attention deficits, sleep disruptions, and specific dopamine imbalances in ...

Consider adenosine A 2A receptor antagonists, for example, which are being evaluated as an adjuvant therapy to L-dopa or D 2 receptor agonists for Parkinson's disease, based on the evidence of ...

New Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine D2 receptors, but KarXT is one of a clutch of new therapies emerging from the pharma ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...